PCL, Inc. Company Description
PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services.
The company offers HiSU solution, an automated multi-immune diagnostic system that performs various diagnostics, high-speed tests including blood screening, multiple cancer screening, autoimmune testing, etc. It also provides antigen and antibody diagnostic kits, including PCLOK II anti-HIV/HCV/syphilis, and PCLOK II HBsAg/HIV p24.
In addition, the company offers platform services, such as SG ID for identifying novel target substances.
Further, it offers covid-19 solutions, such as PCLMD nCoV one step RT-PCR, PCL COVID19 speed RTPCR, PCLMD ABC multi RTPCR molecular diagnostic kits; PCL COVID19 Ag rapid FIA, and PCL COVID19 Ag gold antigen diagnostic kits; and PCL COVID19 IgG/IgM rapid gold, and PCL COVID19 total Ab EIA antibody diagnostic kits.
PCL, Inc. was incorporated in 2008 and is headquartered in Seoul, South Korea.
| Country | South Korea | 
| Founded | 2008 | 
| Industry | Medical Devices | 
| Sector | Healthcare | 
| Employees | 31 | 
| CEO | Soyeon Kim | 
Contact Details
| Address: Star Valley, 99 Seoul, 08510 South Korea | |
| Phone | 82 2 2144 3901 | 
| Website | pclchip.com | 
Stock Details
| Ticker Symbol | 241820 | 
| Exchange | KOSDAQ | 
| Stock Type | Common Stock | 
| Fiscal Year | January - December | 
| Reporting Currency | KRW | 
| ISIN Number | KR7241820000 | 
| SIC Code | 2835 | 
Key Executives
| Name | Position | 
|---|---|
| Soyeon Kim | Chief Executive Officer |